A platelet-inspired paradigm for nanomedicine targeted to multiple diseases

Nanomedicine

Volumn 8, Issue 10, 2013, Pages 1709-1727

  Modery Pawlowski, Christa L ^a   Kuo, Hsiao Hsuan ^b   Baldwin, William M ^b   Gupta, Anirban Sen ^a  

^a Case Western Reserve University   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

drug delivery; hemostasis; immune response; inflammation; metastasis; platelet; platelet inspired nanomedicine; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA THROMBOGLOBULIN; BIOMATERIAL; CD40 LIGAND; COLLAGEN TYPE 4; COLONY STIMULATING FACTOR 1; DEXAMETHASONE; FIBRIN; FIBRINOGEN; FIBRONECTIN; IMMUNOLIPOSOME; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PENTAPEPTIDE; PHOSPHOSERINE; PLATELET DERIVED GROWTH FACTOR; POLYLACTIC ACID; RANTES; SALICYLIC ACID; TACROLIMUS; THROMBIN; THROMBOXANE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADAPTIVE IMMUNITY; ARTERY THROMBOSIS; ARTHRITIS; ATHEROSCLEROSIS; BLOOD CLOT RETRACTION; BLOOD VESSEL OCCLUSION; CELL INTERACTION; COLITIS; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HEMOSTASIS; HUMAN; HYPERACTIVITY; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; KIDNEY ISCHEMIA; METASTASIS; MICROENVIRONMENT; NANOMEDICINE; NONHUMAN; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THERAPY EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOPHLEBITIS; THROMBOSIS;

BLOOD PLATELETS; HEMORRHAGE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NANOMEDICINE; NEOPLASM METASTASIS;

EID: 84885130360     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.113     Document Type: Review

References (127)

1. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br. J. Haematol. 134(5), 453-466 (2006).
2. Platelets. Michelson AD (Ed.). Academic Press, CA, USA (2012).
3. Ruggeri ZM. Platelets in atherothrombosis. Nat. Med. 8(11), 1227-1234 (2002).
4. Smyth SS, McEver RP, Weyrich AS et al. Platelet functions beyond hemostasis. J. Thromb. Haemost. 7(11), 1759-1766 (2009).
5. Ware J, Suva LJ. Platelets to hemostasis and beyond. Blood 117(14), 3703-3704 (2011).
6. Italiano JE, Bergmeier W, Tiwari S et al. Mechanisms and implications of platelet discoid shape. Blood 101(12), 4789-4796 (2003).
7. Radmacher M, Fritz M, Kacher CM, Cleveland JP, Hansma PK. Measuring the viscoelastic properties of human platelets with the atomic force microscope. Biophys. J. 70(1), 556-567 (1996).
8. Tokarev AA, Butylin AA, Ermakova EA, Shnol EE, Panasenko GP, Ataullakhanov FI. Finite platelet size could be responsible for platelet margination effect. Biophys. J. 101(8), 1835-1843 (2011).
9. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 16(1), 58-83 (2009).
10. Kuwahara M, Sugimoto M, Tsuji S et al. Platelet shape changes and adhesion under high shear flow. Arterioscler. Thromb. Vasc. Biol. 22(2), 329-334 (2002).
11. Mackman N. Triggers, targets and treatments for thrombosis. Nature 451(7181), 914-918 (2008).
12. D'Souza SE, Ginsberg MH, Matsueda GR, Plow EF. A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 350(6313), 66-68 (1991).
13. Monroe D, Hoffman M, Roberts H. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 22, 1381-1389 (2002).
14. Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr. Med. Chem. 11(17), 2245-2260 (2004).
15. Modery-Pawlowski CL, Tian LL, Pan V, McCrae KR, Mitragotri S, Sen Gupta A. Approaches to synthetic platelet analogs. Biomaterials 34(2), 526-541 (2012).
16. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ. Res. 100(12), 1673-1685 (2007).
17. Okamura Y, Handa M, Suzuki H, Ikeda Y, Takeoka S. New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: Cooperative effects of a mixed system of fibrinogen gamma-chain dodecapeptide- or glycoprotein Ibalpha-conjugated latex beads under flow conditions. J. Artif. Organs 9(4), 251-258 (2006).
18. Nishiya T, Kainoh M, Murata M, Handa M, Ikeda Y. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: Specific synergy of receptor-ligand interactions. Blood 100(1), 136-142 (2002).
19. Ravikumar M, Modery CL, Wong TL, Sen Gupta A. Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes. Bioconjug. Chem. 23(6), 1266-1275 (2012).
20. Ravikumar M, Modery CL, Wong TL, Sen Gupta A. Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro. Biomacromolecules. 13(5), 1495-1502 (2012).
21. Modery-Pawlowski CL, Tian LL, Ravikumar M, Wong TL, Sen Gupta A. In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct. Biomaterials 34(12), 3031-3041 (2013).
22. Decuzzi P, Lee S, Bhushan B, Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 33(2), 179-190 (2005).
23. Tao L, Hu W, Liu Y, Huang G, Sumer BD, Gao J. Shape-specific polymeric nanomedicine: Emerging opportunities and challenges. Exp. Biol. Med. (Maywood). 236(1), 20-29 (2011).
24. Charoenphol P, Mocherla S, Bouis D, Namdee K, Pinsky DJ, Eniola-Adefeso O. Targeting therapeutics to the vascular wall in atherosclerosis - carrier size matters. Atherosclerosis 217(2), 364-370 (2011).
25. Nesbitt WS, Westein E, Tovar-Lopez FJ et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat. Med. 15(6), 665-673 (2009).
26. Doshi N, Orje JN, Molins B, Smith JW, Mitragorti S, Ruggeri ZM. Platelet mimetic particles for targeting thrombi in flowing blood. Adv. Mater. 24(28), 3864-3869 (2012).
27. Chiu GNC, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim. Biophys. Acta. 1613(1-2), 115-121 (2003).
28. Okamura Y, Katsuno S, Suzuki H et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute. J. Control. Release 148(3), 373-379 (2010).
29. Kona S, Dong JF, Liu Y, Tan J, Nguyen KT. Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int. J. Pharm. 423(2), 516-524 (2012).
30. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 23(12), 2131-2137 (2003).
31. Meijden PEJ, Heemskerk JWM, Hamulyák K, Cate H. Classification of venous thromboembolism (VTE). Platelets in venous thrombosis. J. Thromb. Haemost. 3(11), 2575-2577 (2005).
32. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J. Am. Coll. Cardiol. 28(7), 1643-1651 (1996).
33. Weyrich AS, Prescott SM, Zimmerman GA. Platelets, endothelial cells, inflammatory chemokines, and restenosis: Complex signaling in the vascular play book. Circulation 106(12), 1433-1435 (2002).
34. Massberg S, Brand K, Gruner S et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 196(7), 887-896 (2002).
35. Merten M, Thiagarajan P. P-selectin in arterial thrombosis. Z. Kardiol. 93(11), 855-863 (2004).
36. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J. 24(24), 2166-2179 (2003).
37. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J. Thromb. Haemost. 10(2), 167-176 (2012).
38. Lowe G. Virchow's triad revisited: Abnormal flow. Pathophysiol. Haemost. Thromb. 33(5-6), 455-457 (2003).
39. Jerjes-Sanchez C. Venous and arterial thrombosis: A continuous spectrum of the same disease? Eur. Heart J. 26(1), 3-4 (2005).
40. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler. Thromb. Vasc. Biol. 30(12), 2357-2361 (2010).
41. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc. Res. 59(4), 812-823 (2003).
42. Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb. Res. 121(4), 535-542 (2008).
43. Demos SM, Alkan-Onyuksel H, Kane BJ et al. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J. Am. Coll. Cardiol. 33(3), 867-875 (1999).
44. Klegerman ME, Zou Y, McPherson DD. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator. J. Liposome Res. 18(2), 95-112 (2008).
45. Heeremans JL, Prevost R, Bekkers ME et al. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: A comparison with free t-PA. Thromb. Haemost. 73(3), 488-494 (1995).
46. Leach JK, O'Rear EA, Patterson E, Miao Y, Johnson AE. Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb. Haemost. 90(1), 64-70 (2003).
47. Peters D, Kastantin M, Kotamraju VR et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc. Natl Acad. Sci. USA 106(24), 9815-9819 (2009).
48. Yu X, Song SK, Chen J et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn. Reson. Med. 44(6), 867-872 (2000).
49. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 60(11), 1241-1251 (2008).
50. Lanza GM, Yu X, Winter PM et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: Implications for rational therapy of restenosis. Circulation 106(22), 2842-2847 (2002).
51. Alonso A, Della Martina A, Stroick M et al. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 38(5), 1508-1514 (2007).
52. Sen Gupta A, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb. Haemost. 93(1), 106-114 (2005).
53. Huang G, Zhou Z, Srinivasan R et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 29(11), 1676-1685 (2008).
54. Srinivasan R, Marchant RE, Sen Gupta A. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J. Biomed. Mater. Res. A 93(3), 1004-1015.
55. Modery CL, Ravikumar M, Wong TL, Dzuricky MJ, Durongkaveroj N, Sen Gupta A. Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. Biomaterials 32(35), 9504-9514 (2011).
56. Kawata H, Uesugi Y, Soeda T et al. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound. J. Am. Coll. Cardiol. 60(24), 2550-2557 (2012).
57. Chan JM, Zhang L, Tong R et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl Acad. Sci. USA 107(5), 2213-2218 (2010).
58. Korin N, Kanapathipillai M, Matthews BD et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337(6095), 738-742 (2012).
59. Sen Gupta A. Nanomedicine approaches in vascular disease: A review. Nanomedicine 7(6), 763-779 (2011).
60. Klinger MHF, Jelkmann W. Role of blood platelets in infection and inflammation. J. Interferon Cytokine Res. 22(9), 913-922 (2002).
61. Petersen F, Bock L, Flad HD, Brandt E. Platelet factor 4-induced neutrophil-endothelial cell interaction: Involvement of mechanisms and functional consequences different from those elicited by interleukin-8. Blood 94(12), 4020-4028 (1999).
62. Brindley LL, Sweet JM, Goetzl EJ. Stimulation of histamine release from human basophils by human platelet factor 4. J. Clin. Invest. 72(4), 1218-1223 (1983).
63. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv. Immunol. 55, 97-179 (1994).
64. Piccardoni P, Evangelista V, Piccoli A, de Gaetano G, Walz A, Cerletti C. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Thromb. Haemost. 76(5), 780-785 (1996).
65. von Hundelshausen P, Weber KS, Huo Y et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103(13), 1772-1777 (2001).
66. Gawaz M, Brand K, Dickfeld T et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 148(1), 75-85 (2000).
67. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: Old players in new games. Immunol. Rev. 177, 204-216 (2000).
68. Wahl SM, Hunt DA, Wakefield LM et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc. Natl Acad. Sci. USA 84(16), 5788-5792 (1987).
69. Soma Y, Takehara K, Ishibashi Y. Alteration of the chemotactic response of human skin fibroblasts to PDGF by growth factors. Exp. Cell Res. 212(2), 274-277 (1994).
70. Furman MI, Benoit SE, Barnard MR et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J. Am. Coll. Cardiol. 31(2), 352-358 (1998).
71. Blanks JE, Moll T, Eytner R, Vestweber D. Stimulation of P-selectin glycoprotein ligand-1 on mouse neutrophils activates beta 2-integrin mediated cell attachment to ICAM-1. Eur. J. Immunol. 28(2), 433-443 (1998).
72. Kuijper PH, Gallardo Tores HI, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ. Platelet associated fibrinogen and ICAM-2 induce firm adhesion of neutrophils under flow conditions. Thromb. Haemost. 80(3), 443-448 (1998).
73. van Kooten C, Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 67(1), 2-17 (2000).
74. Barnes PJ. New aspects of asthma. J. Intern. Med. 231(5), 453-461 (1992).
75. Endresen GK. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol. Int. 9(1), 19-24 (1989).
76. Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N. Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: Interaction with platelets. J. Rheumatol. 31(12), 2347-2355 (2004).
77. Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 106(4), 840-845 (1994).
78. Kirsten A, Watz H, Kretschmar G et al. Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects - a double blind, randomized, placebo-controlled, cross-over clinical trial. Pulm. Pharmacol. Ther. 24(5), 555-558 (2011).
79. Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb. Res. 111(3), 165-170 (2003).
80. Boilard E, Nigrovic PA, Larabee K et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327(5965), 580-583 (2010).
81. Kaila N, Janz K, DeBernardo S et al. Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. J. Med. Chem. 50(1), 21-39 (2007).
82. Sumariwalla PF, Malfait AM, Feldmann M. P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor. Clin. Exp. Immunol. 136(1), 67-75 (2004).
83. Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 38(9), 818-825 (1999).
84. Metselaar JM, Wauben MHM, Wagenaar-Hilbers JPA, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 48(7), 2059-2066 (2003).
85. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther. 315(1), 196-202 (2005).
86. Jubeh TT, Barenholz Y, Rubinstein A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm. Res. 21(3), 447-453 (2004).
87. Koning GA, Schiffelers RM, Wauben MHM et al. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 54(4), 1198-1208 (2006).
88. Minaguchi J, Oohashi T, Inagawa K, Ohtsuka A, Ninomiya Y. Transvascular accumulation of Sialyl Lewis X conjugated liposome in inflamed joints of collagen antibody-induced arthritic (CAIA) mice. Arch. Histol. Cytol. 71(3), 195-203 (2008).
89. Sakhalkar HS, Dalal MK, Salem AK et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA 100(26), 15895-15900 (2003).
90. Baldwin WM, Kuo H-H, Morrell CN. Platelets: Versatile modifiers of innate and adaptive immune responses to transplants. Curr. Opin. Organ Transplant. 16(1), 41-46 (2011).
91. Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV. Ischemia/reperfusion injury in human kidney transplantation: An immunohistochemical analysis of changes after reperfusion. Am. J. Pathol. 153(2), 557-566 (1998).
92. Jassem W, Koo DDH, Cerundolo L, Rela M, Heaton ND, Fuggle SV. Cadaveric versus living-donor livers: Differences in inflammatory markers after transplantation. Transplantation 76(11), 1599-1603 (2003).
93. Meehan SM, Limsrichamrern S, Manaligod JR et al. Platelets and capillary injury in acute humoral rejection of renal allografts. Hum. Pathol. 34(6), 533-540 (2003).
94. Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J. 15(13), 2337-2344 (2001).
95. Morrell CN, Murata K, Swaim AM et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ. Res. 102(7), 777-785 (2008).
96. Swaim AF, Field DJ, Fox-Talbot K, Baldwin WM, Morrell CN. Platelets contribute to allograft rejection through glutamate receptor signaling. J. Immunol. 185(11), 6999-7006 (2010).
97. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N. Engl. J. Med. 363(15), 1451-1462 (2010).
98. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J. Biol. Chem. 264(15), 9053-9060 (1989).
99. Yamakuchi M, Kirkiles-Smith NC, Ferlito M et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc. Natl Acad. Sci. USA 104(4), 1301-1306 (2007).
100. Morrell CN, Sun H, Swaim AM, Baldwin WM. Platelets an inflammatory force in transplantation. Am. J. Transplant. 7(11), 2447-2454 (2007).
101. Kuo HH, Morrell CN, Baldwin WM. Alloantibody induced platelet responses in transplants: Potent mediators in small packages. Hum. Immunol. 73(12), 1233-1238 (2012).
102. Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J. Clin. Invest. 116(3), 769-774 (2006).
103. Baganz NL, Blakely RD. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem. Neurosci. 4(1), 48-63 (2013).
104. Dees C, Akhmetshina A, Zerr P et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208(5), 961-972 (2011).
105. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat. Rev. Immunol. 11(4), 264-274 (2011).
106. Garraud O, Chavarin P, Fabrigil P, Hamzeh Cognasse H, Congnasse F. Novel functions of therapeutic platelets as "immune cells". J. Blood Disord. Transfusion S1, 1-6 (2011).
107. Asgeirsdóttir SA, Zwiers PJ, Morselt HW et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Physiol. Renal Physiol. 294(3), F554-F561 (2008).
108. Baldwin WM, Kasper EK, Zachary AA, Wasowska BA, Rodriguez ER. Beyond C4d: Other complement-related diagnostic approaches to antibody-mediated rejection. Am. J. Transplant. 4(3), 311-318 (2004).
109. Collier BD, Adams MB, Kauffman HM et al. Accurate diagnosis of renal transplant rejection by indium-111 platelet imaging despite postoperative cyclosporin therapy. Clin. Nucl. Med. 13(8), 606-610 (1988).
110. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat. Rev. Cancer 4(6), 448-456 (2004).
111. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet - cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br. J. Pharmacol. 143(7), 819-826 (2004).
112. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J. Thromb. Haemost. 9(2), 237-249 (2011).
113. Konstantopoulos K, Thomas SN. Cancer cells in transit: The vascular interactions of tumor cells. Annu Rev Biomed Eng. 11, 177-202 (2009).
114. Varki A. Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood 110(6), 1723-1729 (2007).
115. Billroth T. Lectures on Surgical Pathology And Therapeutics: A Handbook For Students and Practictioners (8th Edition). The New Sydenham Society, London, UK (1878).
116. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 61(1), 46-52 (1968).
117. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J Involvement of platelets in tumour angiogenesis? Lancet 352(9142), 1775-1777 (1998).
118. Gay LJ, Felding-habermann B. Contribtion of platelets to tumour metastasis. Cancer. 11(2), 123-134 (2011).
119. Modery-Pawlowski CL, Master AM, Pan V, Howard GP, Sen Gupta A. A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms. Biomacromolecules 14(3), 910-919 (2013).
120. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5), 576-590 (2011).
121. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25(1), 9-34 (2006).
122. Palumbo JS, Talmage KE, Massari J V et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105(1), 178-185 (2005).
123. Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: The role of physical interactions and mechanical forces in metastasis. Nat. Rev. Cancer 11(7), 512-522 (2011).
124. Amirkhosravi A, Mousa SA, Amaya M et al. Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol. Biol. 663, 241-259 (2010).
125. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: Approaches to isolation and characterization. J. Cell Biol. 192(3), 373-382 (2011).
126. Schroeder A, Heller DA, Winslow MM et al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer. 12(1), 39-50 (2012).
127. Huang Z, King MR. An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation. Gene Ther. 16(10), 1271-1282 (2009).